A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorAtridia Pty Ltd.

About this trial

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.

Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.

Adequate bone marrow and other vital organ functions

Adequate liver function tests

HR-positive or HER2-negative solid tumor patients

Plan to receive any other anti-tumor therapy during the study.

Active brain metastases .

Have poorly controlled or severe cardiovascular disease, including (1) congestive heart failure.

Previous use of fulvestrant

15 Participants

are divided into 1 treatment group

Atridia Pty Ltd.

Lead sponsor